提前暂停低血糖胰岛素泵技术在易发生低血糖的1型糖尿病成人中的有效性与安全性(SMILE)
SMILE是一项开放标签随机对照试验,纳入153例易发生低血糖的1型糖尿病成人,随机分为带提前暂停低血糖功能的胰岛素泵联合实时CGM组或仅胰岛素泵联合自我血糖监测组,治疗6个月。结果显示干预组低血糖事件和严重低血糖事件显著减少,无严重设备相关不良事件或糖尿病酮症酸中毒。
要点
- 提前暂停低血糖功能联合实时CGM可显著减少传感器低血糖事件。
- 严重低血糖事件(需第三方协助)在干预组显著少于对照组。
- 无严重设备相关不良事件或糖尿病酮症酸中毒报告。
核心结论
- 在易发生低血糖的1型糖尿病成人中,带提前暂停低血糖功能的胰岛素泵联合实时CGM较无实时CGM的持续皮下胰岛素输注显著减少传感器低血糖和严重低血糖事件。
研究设计与样本
- 来自加拿大、法国、意大利、荷兰和英国的16个中心,基线2周导入期后随机分配,干预6个月。
主要发现
- 最常见不良事件为低血糖(对照组10/77 [13%] vs 干预组4/76 [5%])和高血糖(两组均为7/77 [9%] vs 7/76 [9%])。
- 未报告严重设备相关不良事件或糖尿病酮症酸中毒事件。
关键数值与推荐
- 高低血糖风险定义为近期严重低血糖或Clarke/Gold评分≥4。
- 主要结局为每周每参与者传感器低血糖事件平均次数。
临床怎么用
- 对于易发生低血糖的1型糖尿病成人,可考虑使用带提前暂停低血糖功能的胰岛素泵联合实时CGM以降低低血糖风险。
- 该技术在高低血糖风险人群中可能带来获益,但需结合个体情况评估。
局限性
- 开放标签设计,参与者和治疗医生未设盲,可能引入偏倚。
- 研究由Medtronic资助,可能存在利益冲突。
- 随访时间6个月,长期效果未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypoglycaemia unawareness and severe hypoglycaemia can increase fear of hypoglycaemia and the risk of subsequent hypoglycaemic events. We aimed to assess the safety and efficacy of insulin pump therapy with integrated continuous glucose monitoring (CGM) and a suspend-before-low feature (Medtronic MiniMed 640G with SmartGuard) in hypoglycaemia-prone adults with type 1 diabetes. METHODS: SMILE was an open-label randomised controlled trial done in people aged 24-75 years with type 1 diabetes for 10 years or longer, HbA1c values of 5·8-10·0% (40-86 mmol/mol), and at high risk of hypoglycaemia (recent severe hypoglycaemia or hypoglycaemia unawareness defined by a Clarke or Gold score ≥4). Participants were enrolled from 16 centres (eg, clinics, hospitals, or university medical centres) in Canada, France, Italy, the Netherlands, and the UK. After baseline run-in phase (2 weeks), participants were randomly assigned to the MiniMed 640G pump (continuous subcutaneous insulin infusion) with self-monitoring of blood glucose (control group) or to the MiniMed 640G system with the suspend-before-low feature enabled (intervention group), for 6 months. The study statistician analysing the data was masked to group assignment until final database lock; because of the nature of the intervention, participants and treating clinicians could not be masked to group assignment. The primary outcome was the mean number of sensor hypoglycaemic events, defined as 55 mg/dL (3·1 mmol/L) or lower, and was analysed on an intention-to-treat basis in all randomly assigned participants. This trial is registered with ClinicalTrials.gov, number NCT02733991, and is completed. FINDINGS: Between Dec 7, 2016, and March 27, 2018, 153 participants with a mean age 48·2 [12·4] years were randomly assigned: 77 to the control group (mean age 47·4 [12·5] years) and 76 to the intervention group (mean age 49·0 [12·2] years). After 6 months, the intervention group had significantly fewer hypoglycaemic events per participant per week (1·1 [SD 1·2] vs 4·1 [3·4] mean events, model-based treatment effect -2·9 [95% CI -3·5 to -2·3]; p<0·0001) and fewer severe hypoglycaemic events (instances requiring third-party assistance with carbohydrate or glucagon administration, or other resuscitative actions) overall (three vs 18; p=0·0036). The most common adverse events were hypoglycaemia (observed in ten [13%] of 77 participants in the control group vs four [5%] of 76 in the intervention group) and hyperglycaemia (observed in seven [9%] of 77 vs seven [9%] of 76). No serious adverse device effects or episodes of diabetic ketoacidosis were reported. INTERPRETATION: Insulin pump therapy with integrated CGM and a suspend-before-low feature reduced the frequency of sensor hypoglycaemic and severe hypoglycaemic events in hypoglycaemia-prone adults compared with use of continuous subcutaneous insulin infusion without real-time CGM. These results suggest that this technology could be beneficial in this high-risk population. FUNDING: Medtronic International Trading Sàrl and Medtronic Canada.
引用
- Bosi E, Choudhary P, de Valk HW, et al. Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial. Lancet Diabetes Endocrinol. 2019. PMID: 31047902. doi:10.1016/S2213-8587(19)30150-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。